The size and complexity of CENTER-TBI necessitates a strong management structure. This will be implemented by close collaboration between Prof. Andrew Maas (UZA), the Project Coordinator and Prof. David Menon (UCAM) who will act as vice coordinator and co-chairman of the Management Committee. Their work will be supported by a Management Committee which will act as the executive body for the project, and facilitate coordination and integration of activities of all participants. In contrast to other, less complex collaborative projects, the Management Committee will be the decision making body of the consortium. This organisation will promote and efficient and effective management for this complex project. The Management Committee will report on project progress and is accountable to the General Assembly.
Prof. Andrew I.R. Maas from the Antwerp University Hospital will be the Project Coordinator of CENTER-TBI. He is the intermediary between the European Commission and the Consortium and as such will be responsible for all scientific activities of the consortium. Supervision of the overall progress of the project will be conducted in close collaboration with Prof. David Menon form the University of Cambridge as co-chairman of the Management Committee. Véronique De Keyser from the Antwerp University Hospital is the logistic and administrative coordinator for CENTER-TBI.
Representatives of the investigators (non-voting members of the MC):
The management team works closely with the scientific leaders of the Work Packages that form the core of the CENTER-TBI project.
The list of Work Packages and their leaders is:
|WP 1||TBI across Europe:CENTER-TBI Core Study & Registry||Andrew Maas|
|WP 2||Provider profiling and descriptive analyses||Ewout Steyerberg|
|WP 3||Genomics||Aarno Palotie|
|WP 4||Neuro-imaging||Jan Verheyden|
|WP 5||Biomarkers||Andras Buki|
|WP 6||ICU physiome: Optimising monitoring and treatment||Nino Stocchetti|
|WP 7||Epidemiology of TBI in Europe||Marek Majdan|
|WP 8||Phenotyping by CT and MR||David Menon|
|WP 9||Coagulopathy and platelet dysfunction||Marc Maegele|
|WP 10||Multi-dimensional outcome assessment||Nicole Von Steinbüchel|
|WP 11||Health utility indices and population health||Suzanne Polinder|
|WP 12||Disease characterisaion and outcome prediction||Ewout Steyerberg|
|WP 13||Effective clinical care and Precision Medicine||Hester Lingsma|
|WP 14||Transitions of care and post-acute care||Olli Tenovuo|
|WP 15||Prediction of recovery from coma and outcome||Louis Puybasset|
|WP 16||Embedded trials and associated studies||David Menon|
|WP 17||Internal and external validation of findings||Fiona Lecky|
|WP 18||Knowledge transfer and guideline development||Andrew Maas|
|WP 19||Communication, Education, Dissemination & Implementation||Giuseppe Citerio|
|WP 20||Neuroinformatics and biostatistics platform||Mathew Abrams|
|WP 22||International standardization and integration||Andrew Maas|
The General Assembly is composed of all involved Participants. Each Participant has one vote.
The General Assembly consists of one representative of each Participant with authority to vote. All other non-voting researchers working for this project may join the meetings and discussions. The General Assembly is the body approving and amending decisions made by the Coordinators and/or the Management Committee. The main tasks of the General Assembly are:
The CENTER-TBI project consists of 37 participants and 10 associated participants, who will contribute their expertise and time to the project.
The CENTER-TBI participants will perform the scientific analyses.
The Scientific Advisory Board (SAB) forms an important component of CENTER-TBI. The main role of the Advisory Board is to act as a sounding board for the Participants as ideas and results flow from the project. The Advisory Board will also help to maintain an appropriate balance between scientific and patient perspectives in the real world of the clinical management of patients with TBI. We recognize that much collective knowledge and wisdom is available amongst the Participants of CENTER-TBI, but place great value on an external and independent body to guide and support the Coordinators and Participants in this complex project.
The Scientific Advisory Board will consist of methodological and clinical experts as well as representatives of patient organisations. The Scientific Advisory Board will also include a member with ethical expertise who will also assume the role of external independent ethics advisor for the project and regulatory/pharmaceutical expert.
The Scientific Advisory Board will ensure a high standard of research and monitor the progress of the project by taking part in the annual General Assembly meetings and discussing progress and problems directly with the Management Committee. Whenever appropriate, it will consult the consortium and make recommendations as to improve their performance.
Los Angeles, US
New York, US